Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2023; 13(12): 223-231


Evaluation on antioxidative and neuroprotective activity of bacoside- A, Asiatic acid and kaempferol in endothelin-1 induced cerebral ischemia in rat

Ashutosh Ghosh, Nasima Khanam, Debjani Nath.




Abstract
Cited by 0 Articles

The framework of the present study was mapped out to evaluate the neuroprotective efficacy of bacoside-A, Asiatic acid, and kaempferol as antioxidants in the endothelin-1 (ET-1) induced focal cerebral ischemic brain of rats. Oral administration of bacoside-A (50 mg/kg), Asiatic acid (50 mg/kg), and kaempferol (50 mg/kg) significantly reduced the infarct volume to 31.8% ± 1.30%, 32.3% ± 1.25%, and 34.06% ± 1.30%, respectively, compared to the vehicle–treated ischemic (I/R) group. The neurological deficit was significantly reduced and the neuropathological condition of microglia and astrocytes were also improved. Significant increases in calcium levels and malondialdehyde and reduction (p < 0.01) at the levels of antioxidative enzymes superoxide dismutase, catalase and reduced glutathione were observed. Considering the level of efficacy, Bacoside-A was found to be the most potent neuroprotective antioxidant among the three phytochemicals.

Key words: Cerebral ischemia, bacoside-A, asiatic acid, kaempferol, infarct volume, neuroprotective






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.